AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04820231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intra-articular PRP injection
Study NCT01679912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone to the call center
Description: recommendations to phone to the call center for all the patients who have an acute attack
Study NCT02787759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hands-Free Walking
Description: Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
Study NCT02787759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge Based plus Hands-Free'
Description: Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
Study NCT01764698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM-SUD
Description: 6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
Study NCT01764698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
Study NCT01938898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Invitation letter randomisation
Description: There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~1. Male \& Study \& Confidentiality~2. Male \& Study~3. Male \& Project \& Confidentiality~4. Male \& Project~5. Female \& Project \& Confidentiality~6. Female \& Project~7. Female \& Study \& Confidentiality~8. Female \& Study~9. Neutral \& Study \& Confidentiality~10. Neutral \& Study~11. Neutral \& Project \& Confidentiality~12. Neutral \& Project
Study NCT01351883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: ANOM
Description: the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
Study NCT01359722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
Study NCT01359722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive only the infusion of saline in the same doses and infusion rate.
Study NCT03847480 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET guided dose painting
Description: The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
Study NCT00944892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: 2 Administrations of REGN475 within 24 weeks.
Study NCT00944892 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match REGN475 doses
Study NCT01293383 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LEO 90105
Description: Ointment
Study NCT00762645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (Travatan)
Description: One drop in each eye, once daily at 9 AM
Study NCT00762645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine 1%
Description: One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
Study NCT02915562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Study NCT01620307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus (Rapamune 2mg/day, Pfizer)
Description: Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
Study NCT01620307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus (Rapamune 2mg/day, Pfizer)
Description: Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
Study NCT04885426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose metformin
Description: Metformin Pill 250mg/day
Study NCT04885426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose metformin
Description: Metformin Pill 500mg/day
Study NCT04885426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03075098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital colposcope
Description: Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
Study NCT02896101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus Cream, 1%
Study NCT02896101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel® (pimecrolimus) Cream
Study NCT02896101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Pimecrolimus Cream, 1%
Study NCT01215032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Taken orally twice daily each 28-day cycle, for 12 cycles
Study NCT02041312 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be needed.
Study NCT04459221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9, 9-Valent Intramuscular Suspension
Description: access to HPV vaccination near the college in a health bus
Study NCT00983892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver website
Description: Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
Study NCT03618706 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy
Description: After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.
Study NCT03020056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phacolin eye drops
Description: After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
Study NCT03020056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
Study NCT01588210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sealant application
Description: A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.
Study NCT01588210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sealant application
Description: A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.
Study NCT01588210 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sealant application
Description: A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.
Study NCT01674803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: biodegradable polymer sirolimus eluting stent
Study NCT01674803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy
Description: biodegradable polymer everolimus eluting stent
Study NCT01674803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity
Description: durable polymer zotarolimus-eluting stent
Study NCT02736955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Study NCT01665599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 999303)
Study NCT00357318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT00357318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00357318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00357318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01187147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
Study NCT03653091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing (DMR)
Description: The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
Study NCT03653091 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing Sham (Sham)
Description: The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
Study NCT02710344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Program
Description: Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
Study NCT02083679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine
Description: Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m\^2 on Day 1 plus gemcitabine 1250 mg/m\^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Study NCT02083679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Study NCT02083679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Study NCT02083679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Study NCT02257918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
Study NCT02257918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
Study NCT05402618 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention.
Study NCT03979547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down.
Study NCT00135785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Study NCT00135785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03965221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LYNX
Description: Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
Study NCT03965221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyChoices
Description: Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
Study NCT04318314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COPAN swabbing and blood sample collection
Description: COPAN swabbing of nostrils and/or oropharynx and blood sample collection
Study NCT02068378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMPE Optical Sensor Device
Description: Christie Medical Physics \& Enginieering visual feedback with optical sensing device.
Study NCT01674452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based group (HBG)
Description: Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
Study NCT01674452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supervised exercise group (SEG)
Description: Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
Study NCT01032356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Extension Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study NCT04107181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Introducer calla device
Description: The research introducer will be used after the patient consents prior to the annual pap smear.
Study NCT04107181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviews only
Description: Healthy volunteer interviews
Study NCT00691678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin
Description: 400mg chondroitin three times a day (TID) for twenty-four weeks
Study NCT00691678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine
Description: 500mg glucosamine TID for twenty-four weeks
Study NCT02872519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)
Description: Given by IV
Study NCT02872519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo scan
Study NCT02872519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Laboratory Biomarker Analysis
Study NCT01817712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement & Support
Description: IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation.
Study NCT01817712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Transitional Work Program
Description: The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role.
Study NCT05372471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mHealth
Description: ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.
Study NCT05372471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.